<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222181</url>
  </required_header>
  <id_info>
    <org_study_id>24947914.5.0000.5426</org_study_id>
    <nct_id>NCT02222181</nct_id>
  </id_info>
  <brief_title>Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease</brief_title>
  <official_title>Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Brazil, patients with Alzheimer's disease (AD) receiving free drugs of government. Even
      having access to, little is known about the effectiveness, safety and adherence of drug
      therapy in this group of patients. The research aims to promote adherence and develop
      strategies to address Drug-Related Problems (DRP's) in AD patients elderly of reference
      centre for the Elderly of Araraquara. The clinical parameters will be assessed at the
      beginning and after the educational intervention period from April 2014 to April 2015.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dementia is characterized by memory loss associated with cognitive impairment, which directly
      interferes in learning process, social and professional performance, besides being the main
      cause of dementia or Alzheimer's disease (AD). In Brazil, patients are medicated for AD
      through &quot;Programa de Medicamentos Excepcionais&quot; (Exceptional Drug Program) that ensure the
      patient´s treatment by providing high cost medications. Even having access to, little is
      known about the effectiveness, safety and adherence of drug therapy in this group of
      patients. The research aims to promote adherence and develop strategies to address
      Drug-Related Problems (DRP's) in AD patients. For this end, we intend to conduct a
      descriptive, almost experimental and longitudinal uncontrolled research, from April 2014 to
      December 2015, at the CRIA: &quot;Centro de Referência do Idoso de Araraquara&quot; (Reference Centre
      for the Elderly of Araraquara). Patients included in the research must have a diagnosis of AD
      and must be using drugs supplied by the &quot;Programa de Medicamentos Excepcionais&quot;. For data
      collection pharmaceutical care will be employed as a technique, carried out through
      pharmaceutical meetings, including the steps of initial assessment, care plan (pharmaceutical
      intervention) and results evaluation. The results will be monitored for pharmacotherapy
      adherence, cognitive assessment and other clinical parameters related to their health
      problems and resolution of DRP's before and after the proposed follow-up.The expected
      outcomes include knowledge of the medication experiences of AD patients, how they influence
      the adherence and other DRP's and how they can contribute by solving these problems, in
      addition to the impact evaluation of pharmaceutical care in cognitive improving and other
      clinical parameters monitored and evaluated individually.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mini-mental State Examination (MMEE)</measure>
    <time_frame>six months</time_frame>
    <description>MMEE : scale 0-30 ( ≥25 - normal aging; 21-24 - initial stage; 20-10 - middle stage; ≤9 - final stage)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Dementia Rating (CDR)</measure>
    <time_frame>six months</time_frame>
    <description>CDR: scale 1-3 (0-0.5: normal aging; 1- initial stage; 2- middle stage; 3- final stage)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>weekly</time_frame>
    <description>Systolic pressure &lt;140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Total Cholesterol</time_frame>
    <description>Total Cholesterol &lt;200 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>three months</time_frame>
    <description>Normal level: 150mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemia</measure>
    <time_frame>two months</time_frame>
    <description>Normal levels: 70-99mg/dL; diabetic: &gt;121mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>weekly</time_frame>
    <description>Diastolic pressure &lt;90 mmHg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Pharmacotherapy follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with Alzheimer's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacotherapy Management</intervention_name>
    <description>assessment of patient characteristics as alcoholic, smoker, food, drugs
Pharmacotherapy follow-up
to evaluated medication adherence
Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention.</description>
    <arm_group_label>Pharmacotherapy follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly patients who are assisted in CRIA, diagnosed with Alzheimer's in use of
             rivastigmine or donepezil or galantamine, assisted by the &quot;Program for special drugs&quot;.

          -  Be resident in the city of Araraquara / SP

          -  Accept part of pharmacotherapeutic follow-up;

          -  Sign the Statement of Informed Consent Form (ICF).

        Exclusion Criteria:

          -  Fold over pharmacotherapy follow-up;

          -  Being institutionalized;

          -  Patients unable to respond to collection instruments MMSE and CDR data;

          -  Patient without phone contact.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernanda M Oliveira, student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Referência do Idoso de Araraquara - CRIA</name>
      <address>
        <city>Araraquara</city>
        <state>São Paulo</state>
        <zip>14800240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Strand LM, Cipolle RJ, Morley PC. Documenting the clinical pharmacist's activities: back to basics. Drug Intell Clin Pharm. 1988 Jan;22(1):63-7.</citation>
    <PMID>3349924</PMID>
  </reference>
  <reference>
    <citation>Arlt S, Lindner R, Rösler A, von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25(12):1033-47. doi: 10.2165/0002512-200825120-00005. Review.</citation>
    <PMID>19021302</PMID>
  </reference>
  <reference>
    <citation>Lanctôt KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003 Sep 16;169(6):557-64. Review.</citation>
    <PMID>12975222</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <results_first_submitted>April 3, 2016</results_first_submitted>
  <results_first_submitted_qc>April 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2016</results_first_posted>
  <last_update_submitted>April 3, 2016</last_update_submitted>
  <last_update_submitted_qc>April 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Fernanda Mariana de Oliveira</investigator_full_name>
    <investigator_title>Master's degree student</investigator_title>
  </responsible_party>
  <keyword>elderly, medication adherence,pharmaceutical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Experimental, longitudinal and non-randomized study, carried out at Centro de Referência do Idoso de Araraquara (CRIA), from 2014 april to 2015 april, with patients in treatment for Alzheimer's disease.</recruitment_details>
      <pre_assignment_details>Patients were excluded when in advanced or terminal stage of the disease, lived in nursing homes and when it was not possible to contact the patient.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pharmacotherapy Follow-up</title>
          <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>patients in treatment for Alzheimer's disease.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mini-mental State Examination (MMEE)</title>
        <description>MMEE : scale 0-30 ( ≥25 - normal aging; 21-24 - initial stage; 20-10 - middle stage; ≤9 - final stage)</description>
        <time_frame>six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy Follow-up</title>
            <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-mental State Examination (MMEE)</title>
          <description>MMEE : scale 0-30 ( ≥25 - normal aging; 21-24 - initial stage; 20-10 - middle stage; ≤9 - final stage)</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Dementia Rating (CDR)</title>
        <description>CDR: scale 1-3 (0-0.5: normal aging; 1- initial stage; 2- middle stage; 3- final stage)</description>
        <time_frame>six months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy Follow-up</title>
            <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Dementia Rating (CDR)</title>
          <description>CDR: scale 1-3 (0-0.5: normal aging; 1- initial stage; 2- middle stage; 3- final stage)</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic pressure &lt;140 mmHg</description>
        <time_frame>weekly</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy Follow-up</title>
            <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic pressure &lt;140 mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.6" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.7" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol</title>
        <description>Total Cholesterol &lt;200 mg/dL</description>
        <time_frame>Total Cholesterol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy Follow-up</title>
            <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol</title>
          <description>Total Cholesterol &lt;200 mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.2" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.6" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides</title>
        <description>Normal level: 150mg/dL</description>
        <time_frame>three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy Follow-up</title>
            <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides</title>
          <description>Normal level: 150mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.1" spread="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.8" spread="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemia</title>
        <description>Normal levels: 70-99mg/dL; diabetic: &gt;121mg/dL.</description>
        <time_frame>two months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy Follow-up</title>
            <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemia</title>
          <description>Normal levels: 70-99mg/dL; diabetic: &gt;121mg/dL.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.9" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Diastolic pressure &lt;90 mmHg</description>
        <time_frame>weekly</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy Follow-up</title>
            <description>All the patients received pharmacotherapy workup at baseline and after the intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Diastolic pressure &lt;90 mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.49" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.03" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Do not apply.</time_frame>
      <desc>Do not apply.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Do not apply.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fernanda Mariana de Oliveira</name_or_title>
      <organization>Unesp</organization>
      <phone>+551636640217</phone>
      <email>femoliveira12@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

